This common vaccine cuts heart risk nearly in half in new study

The study, a comprehensive analysis of medical data from over 246,822 adults across the United States, focused specifically on individuals diagnosed with atherosclerotic heart disease. This condition, characterized by the progressive buildup of plaque within the arteries, is a leading cause of heart attacks, strokes, and peripheral artery disease, making these patients inherently at higher risk for adverse cardiovascular outcomes. The new data builds upon an accumulating body of evidence that positions the shingles vaccine as a multifaceted preventive tool, potentially reducing the risk of a range of serious health conditions, including not only cardiovascular events but also, as some earlier studies have suggested, even cognitive decline.

Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the lead author of the study, emphasized the consistency of these observations. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke, and death," Dr. Nguyen stated. "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." His remarks highlight the critical importance of these findings for a demographic already contending with significant health challenges and an elevated baseline risk.

The Overlooked Connection: Shingles, Inflammation, and Cardiovascular Health

Atherosclerotic heart disease represents a chronic inflammatory state. The accumulation of fatty plaques, cholesterol, and other substances within artery walls triggers an inflammatory response that can lead to plaque rupture, blood clot formation, and ultimately, severe cardiovascular events. Globally, cardiovascular diseases are the leading cause of death, accounting for an estimated 17.9 million lives each year, with atherosclerotic conditions being a primary driver of this mortality. In the United States alone, approximately 18.2 million adults aged 20 and older have coronary artery disease, the most common type of heart disease.

Shingles, medically known as herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After an initial chickenpox infection, VZV lies dormant in nerve cells and can reactivate years or decades later, typically due to age-related decline in cellular immunity or immunocompromise. The hallmark symptom is a painful rash that usually appears on one side of the body or face. Beyond the acute pain, shingles can lead to severe and long-lasting complications, most notably post-herpetic neuralgia (PHN), a debilitating nerve pain that can persist for months or even years after the rash clears. Other complications include ocular zoster (affecting the eye), Ramsay Hunt syndrome (facial paralysis and hearing loss), and, in rare cases, disseminated zoster affecting internal organs.

The link between shingles and cardiovascular events has become an area of increasing scientific interest. Earlier research has demonstrated that an active shingles infection can induce a systemic inflammatory response and trigger hypercoagulability – an increased tendency for blood clot formation. This pro-thrombotic state is particularly dangerous when occurring in proximity to vital organs like the brain and heart, significantly elevating the risk of ischemic strokes, myocardial infarctions (heart attacks), and venous thromboembolism (VTE). By effectively preventing the shingles infection, the vaccine is hypothesized to mitigate this inflammatory cascade and subsequent clotting risk, thereby indirectly protecting the cardiovascular system.

A Deeper Dive into the Study’s Methodology and Striking Results

To conduct this large-scale investigation, researchers leveraged TriNetX, an extensive federated research network that aggregates de-identified medical records from millions of Americans across numerous healthcare organizations. The study population comprised adults aged 50 years or older with a documented diagnosis of atherosclerotic disease, observed over a period spanning from 2018 to 2025. This timeframe allowed for the inclusion of both the older Zostavax vaccine and the newer, highly effective Shingrix vaccine, which has largely replaced Zostavax in recommendations due to its superior efficacy and durability.

The analysis meticulously compared two cohorts, each consisting of 123,411 individuals: one group had received at least one dose of a shingles vaccine (either Shingrix or Zostavax), while the other group remained unvaccinated. Crucially, the researchers employed sophisticated statistical matching techniques to ensure that both groups were as similar as possible in terms of key demographic variables (such as age, sex, race, and ethnicity) and pre-existing health conditions, including other comorbidities, socioeconomic factors (like housing, economic circumstances, employment, education, and literacy), and medication use. This rigorous methodology aimed to minimize confounding factors and strengthen the causal inference of the findings.

The primary focus of the study was to evaluate heart-related outcomes that occurred between one month and one year following vaccination (or within the equivalent timeframe for the unvaccinated control group). The results were unequivocally clear and statistically significant across all measured endpoints. Vaccinated individuals demonstrated a remarkably lower risk profile:

• 46% reduction in the likelihood of experiencing a major adverse cardiac event (MACE), a composite endpoint typically including heart attack, stroke, or cardiovascular death.
• 66% reduction in all-cause mortality, highlighting a broader protective effect on overall survival.
• 32% reduction in the risk of myocardial infarction (heart attack).
• 25% reduction in the risk of ischemic stroke.
• 25% reduction in the risk of developing heart failure.

These reductions are not merely incremental; they represent a substantial improvement in patient outcomes, particularly for a high-risk population. Dr. Nguyen underscored the magnitude of these benefits, noting that such risk reductions are "comparable to the benefits seen from quitting smoking." This powerful analogy places the shingles vaccine on par with one of the most impactful lifestyle interventions for cardiovascular health, reinforcing its potential as a critical preventive measure.

The Shingles Vaccine Landscape: A Public Health Imperative

The Centers for Disease Control and Prevention (CDC) currently recommends the shingles vaccine for all healthy adults aged 50 years and older, as well as for younger individuals (19 years and older) with weakened immune systems. This recommendation is primarily driven by the vaccine’s efficacy in preventing shingles and its debilitating complication, PHN. Shingrix, the recombinant zoster vaccine, is more than 90% effective in preventing shingles in adults 50 and older, with protection remaining high for at least seven years after vaccination. This high efficacy, coupled with the new evidence of cardiovascular protection, elevates the vaccine’s importance as a public health imperative.

The current findings strongly reinforce the existing CDC guidelines, providing an additional, compelling reason for eligible adults, especially those with pre-existing heart disease, to receive the vaccine. In a climate where vaccine hesitancy and misinformation can pose significant challenges to public health initiatives, studies like this offer concrete, data-driven arguments for vaccination. "Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen stated. "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine."

Limitations, Nuances, and Future Research Horizons

While the study’s findings are robust and compelling, the authors acknowledge certain limitations inherent in observational research. The analysis primarily tracked outcomes during the first year post-vaccination. While this period showed significant benefits, the long-term effects beyond one year warrant further investigation. However, this concern is somewhat mitigated by earlier research, which, while not specifically cited with a 2025 publication date in the original prompt (likely a typo for a prior study), has generally indicated that shingles vaccination can lead to sustained cardiovascular benefits. For instance, other studies have suggested that shingles vaccination is linked to a reduction in cardiovascular events in generally healthy adults, with protective effects potentially lasting for several years.

Another important consideration is the potential for confounding by indication or "healthy vaccinee" bias. Individuals who choose to get vaccinated may, on average, also engage in other healthier behaviors, be more health-conscious, or have better access to healthcare. While the researchers made considerable efforts to adjust for a wide array of health and socioeconomic factors in their statistical modeling, it remains a possibility that some residual confounding influenced the observed benefits. However, the study’s massive sample size, rigorous statistical matching, and the magnitude of the observed risk reductions lend strong credibility to the association between shingles vaccination and reduced cardiovascular risk, suggesting that the vaccine itself plays a significant role independent of other health behaviors.

Broader Implications for Preventive Cardiology and Public Health

The implications of this research extend far beyond individual patient decisions. For preventive cardiology, these findings open new avenues for risk reduction strategies. Incorporating shingles vaccination into routine preventive care for patients with atherosclerotic heart disease could become a standard recommendation, potentially leading to a significant decrease in cardiovascular morbidity and mortality. Healthcare providers, particularly cardiologists and primary care physicians, will be encouraged to proactively discuss shingles vaccination with their eligible patients.

From a public health perspective, these findings underscore the interconnectedness of various health domains. What was once primarily viewed as a neurological or dermatological concern (shingles) is now demonstrating profound systemic benefits, particularly for cardiovascular health. This highlights the importance of a holistic approach to patient care and the potential for existing vaccines to offer unanticipated, yet highly valuable, protective effects.

The economic impact of cardiovascular disease is staggering, with direct and indirect costs reaching hundreds of billions of dollars annually in the U.S. alone. If shingles vaccination can demonstrably reduce serious cardiovascular events, it has the potential to yield substantial cost savings for healthcare systems by preventing hospitalizations, expensive treatments for heart attacks and strokes, and long-term care associated with these conditions.

Further research will undoubtedly explore the precise biological mechanisms underlying these cardioprotective effects. Investigations into inflammatory markers, endothelial function, and coagulation pathways in vaccinated versus unvaccinated individuals could provide deeper insights. Long-term follow-up studies will also be crucial to ascertain the durability of these benefits beyond the one-year mark and to confirm the findings across diverse populations.

Dr. Nguyen will officially present these groundbreaking findings in a session titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease" on Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E, at the American College of Cardiology’s Annual Scientific Session. The presentation is expected to generate significant discussion among cardiovascular specialists and public health experts, potentially catalyzing a renewed focus on the critical role of vaccination in comprehensive cardiovascular disease prevention.